Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 2/20 | 0.65 |
| ▸ | NOS2 | P35228 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 9/20 | 0.50 |
| ▸ | RAB9A | P51151 | 9/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29502836 | 1.00 | NCF1 (0.65) | NCF1NOS2BACE1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL27994035 | 0.98 | NCF1 (0.63) | NCF1NOS2BACE1NPC1RAB9A | |
| SCHEMBL30760998 | 0.81 | NCF1 (0.71) | NCF1NOS2BACE1NPC1RAB9A | |
| SCHEMBL10458402 | 0.81 | NCF1 (0.71) | NCF1NOS2BACE1NPC1RAB9A | |
| SCHEMBL5806618 | 0.79 | NCF1 (0.68) | NCF1NOS2BACE1NPC1RAB9A | |
| SCHEMBL5506476 | 0.79 | NCF1 (1.00) | NCF1NOS2BACE1NPC1RAB9A | |
| SCHEMBL4937771 | 0.77 | NCF1 (0.65) | NCF1NOS2BACE1NPC1RAB9A | |
| SCHEMBL6645329 | 0.77 | NCF1 (0.65) | NCF1NOS2BACE1NPC1RAB9A | |
| SCHEMBL4937770 | 0.77 | NCF1 (0.65) | NCF1NOS2BACE1NPC1RAB9A | |
| SCHEMBL22593292 | 0.77 | NCF1 (0.65) | NCF1NOS2BACE1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 363 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119529846-A | High-performance buffer oxide etching solution and application thereof | 湖北兴福电子材料股份有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-116655530-B | Zinc ion detection fluorescent probe compound and preparation method and application thereof | 南京林业大学 | 2024-08-13 | — | — | CN | claimed |
| EP-4103946-B1 | IN-VITRO DIAGNOSIS OF HISTAMINE INTOLERANCE SYNDROME | IMMUNDIAGNOSTIK AG (DE) | 2024-03-13 | — | — | EP | claimed |
| CN-116908277-A | Application of 2-hydrazinoquinoline as matrix in MALDI-MS analysis of body fluid | 中国科学院化学研究所 | 2023-10-20 | — | — | CN | claimed |
| CN-116854718-A | Organoboron complexes, process for their preparation and their use | 安徽师范大学 | 2023-10-10 | — | — | CN | claimed |
| CN-116655530-A | Zinc ion detection fluorescent probe compound and preparation method and application thereof | 南京林业大学 | 2023-08-29 | — | — | CN | claimed |
| US-20230109016-A1 | IN-VITRO DIAGNOSIS OF HISTAMINE INTOLERANCE SYNDROME | IMMUNDIAGNOSTIK AG (DE) | 2023-04-06 | — | — | US | claimed |
| CN-113735840-B | Hesperetin quinoline hydrazone derivative with anti-tumor activity and preparation method and application thereof | 河南中医药大学 | 2023-01-24 | — | — | CN | claimed |
| CN-113801107-B | Naringenin derivative with anti-tumor activity and preparation and application of Ni (II) complex of naringenin derivative | 河南中医药大学 | 2023-01-17 | — | — | CN | claimed |
| EP-4103946-A1 | IN-VITRO DIAGNOSIS OF HISTAMINE INTOLERANCE SYNDROME | Immundiagnostik AG (DE) | 2022-12-21 | — | — | EP | claimed |
| US-8580516-B2 | Methods and compositions for direct detection of DNA damage | UNIVERSITY OF CHICAGO (US) | 2013-11-12 | — | — | US | claimed |
| EP-2604702-A1 | Methods and compositions for direct detection of DNA damage | The University of Chicago (US) | 2013-06-19 | — | — | EP | claimed |
| US-7981578-B2 | Additive containing photoconductors | XEROX CORPORATION (US) | 2011-07-19 | — | — | US | claimed |
| EP-2334814-A1 | METHODS AND COMPOSITIONS FOR DIRECT DETECTION OF DNA DAMAGE | Solulink Biosciences, Inc. (US) | 2011-06-22 | — | — | EP | claimed |
| US-20100216132-A1 | METHODS AND COMPOSITIONS FOR DIRECT DETECTION OF DNA DAMAGE | UNIVERSITY OF CHICAGO | 2010-08-26 | — | — | US | claimed |
| WO-2010028388-A1 | METHODS AND COMPOSITIONS FOR DIRECT DETECTION OF DNA DAMAGE | SOLULINK BIOSCIENCES, INC. (US) | 2010-03-11 | — | — | WO | claimed |
| US-20090246660-A1 | ADDITIVE CONTAINING PHOTOCONDUCTORS | XEROX CORPORATION (US) | 2009-10-01 | — | — | US | claimed |
| WO-2007104695-A1 | QUINOLIN-4-YLHYDRAZINE DERIVATIVES AS ANTIMALARIAL AGENT | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-09-20 | — | — | WO | claimed |
| US-20060160848-A1 | Method of controlling damage mediated by alpha, beta-unsaturated aldehydes | ADELAIDE, THE UNIVERSITY OF (AU) | 2006-07-20 | — | — | US | claimed |
| WO-2006002473-A1 | METHOD OF CONTROLLING DAMAGE MEDIATED BY ALPHA, BETA-UNSATURATED ALDEHYDES | ADELAIDE RESEARCH & INNOVATION PTY LTD (AU) | 2006-01-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160848-A1 | Method of controlling damage mediated by alpha, beta-unsaturated aldehydes | ALDH2, ALDH1A1, HACL2 | NCF1 724/4885NOS2 1467/4885BACE1 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.